Sir, The development of new fluoroquinolones with enhanced activity against Gram-positive bacteria and anaerobes has given clinicians alternatives for the treatment of severe infections caused by such organisms. Sitafloxacin (DU6859a) is one of the drugs within the new generation of fluoroquinolones. The compound, together with clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin and trovafloxacin, constitutes group IV of the fluoroquinolones according to Naber et al. 1 Sitafloxacin is designed for oncedaily oral administration at a dose of 200 mg, resulting in a mean C max of 1.86 mg/L with a reported t ½ in plasma of 4.6 h.
Sir, The development of new fluoroquinolones with enhanced activity against Gram-positive bacteria and anaerobes has given clinicians alternatives for the treatment of severe infections caused by such organisms. Sitafloxacin (DU6859a) is one of the drugs within the new generation of fluoroquinolones. The compound, together with clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin and trovafloxacin, constitutes group IV of the fluoroquinolones according to Naber et al. 1 Sitafloxacin is designed for oncedaily oral administration at a dose of 200 mg, resulting in a mean C max of 1.86 mg/L with a reported t ½ in plasma of 4.6 h. 2 Analysis of the post-antibiotic effect (PAE) and the bactericidal activity on multiple drug-resistant methicillinresistant Staphylococcus aureus (MRSA) supported the adequacy of the dosing regimen. 2 Owing to the increased use of fluoroquinolones and the alarming numbers of strains that have developed resistance against this class of antimicrobials, many studies have been undertaken to investigate the epidemiology and mechanisms of resistance of bacteria to fluoroquinolones. The prior use of fluoroquinolones was found to be a major risk factor for the isolation of ciprofloxacin-resistant bacteria. 3 A study investigating the in vitro inhibitory activities of sitafloxacin against Streptococcus pneumoniae DNA gyrase and topoisomerase IV found inhibitory activity of this agent against both enzymes, without preference for either of them. 4 Since this suggests that the development of sitafloxacin resistance would require mutations in both enzymes, one should expect the incidence of sitafloxacinresistance to be low. 4 In a study testing 8796 clinical isolates, sitafloxacin showed excellent in vitro activity against Gram-positive bacteria, including MRSA (MIC 50/90 0.25/0.5 mg/L), and compared with other fluoroquinolones, four times higher activity against Enterococcus faecalis (MIC 50/90 0.12/2 mg/L). Sitafloxacin showed at least an equal or slightly better activity than ciprofloxacin against Gram-negative bacteria. Moreover, MICs of sitafloxacin against ciprofloxacin-resistant Enterobacteriaceae were at least three dilution steps lower than those of ciprofloxacin. 5 Sitafloxacin also showed good activity against anaerobic bacteria, including Gram-positive bacteria, i.e. clostridia and peptostreptococci. 6 In the present study, we analysed the antimicrobial susceptibility of 80 clinical isolates of Clostridium difficile. Nineteen strains that were found to be highly resistant to moxifloxacin (MIC 50/90 s у 16 mg/L) were then selected for extended antimicrobial susceptibility testing. For these strains, the MICs of norfloxacin, pefloxacin, ciprofloxacin, fleroxacin, ofloxacin, enoxacin, grepafloxacin, sparfloxacin, gatifloxacin, gemifloxacin, trovafloxacin, moxifloxacin, clinafloxacin and sitafloxacin were determined, employing broth microdilution in accordance with the recommenda- The increase in multidrug-resistant bacteria causing nosocomial infections advocates the need for new compounds with high activity against bacteria carrying multiple resistance genes. Testing 73 ciprofloxacin-resistant Enterococcus faecium strains, Brisse et al. 7 found 36 isolates to be susceptible to sitafloxacin. The results of the study presented here show a high in vitro activity of sitafloxacin against otherwise fluoroquinolone-resistant C. difficile strains. This is another indication of the increased activity of sitafloxacin against Gram-positive bacteria. Further studies are needed to determine whether this antibiotic Correspondence agent is also inhibiting both the DNA gyrase and the topoisomerase IV of C. difficile strains. This would possibly explain its activity against otherwise fluoroquinoloneresistant organisms. The data presented here make sitafloxacin a candidate for clinical evaluation of its therapeutic efficacy in C. difficile infection.
In summary, sitafloxacin demonstrated in vitro activity against Gram-positive and -negative bacteria, suggesting an important role for sitafloxacin in the treatment of infections due to MRSA, enterococci and other multidrugresistant bacteria. However, the increased use of this class of antibiotics and the rapid development of resistance challenges the clinicians with choosing the optimal antibiotic treatment. Additionally, these data should encourage the physician to monitor susceptibility patterns carefully. 
